Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 9, 2013, Pages 693-703

  He, Yan Ling ^a   Kulmatycki, Kenneth ^a   Zhang, Yiming ^b   Zhou, Wei ^b   Reynolds, Christine ^b   Ligueros Saylan, Monica ^b   Taylor, Ann ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

DPP 4 inhibitor; Pharmaco kinetics; Renal impairment; Vildagliptin

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CYTOCHROME P450; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; INSULIN; MITIGLINIDE; SULFONYLUREA; TORASEMIDE; VALSARTAN; VILDAGLIPTIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; HYDROLYSIS; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PAIN; PARALLEL DESIGN; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PROTEIN BINDING; SIDE EFFECT; XEROSTOMIA;

ADAMANTANE; ADULT; AGED; AREA UNDER CURVE; BODY MASS INDEX; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES; RENAL INSUFFICIENCY;

EID: 84876384692     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201885     Document Type: Article

References (35)

1. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept. 1999; 85: 9-24. (Pubitemid 29505281)
2. Deacon C.F., Johnsen AH, Holst JJ Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995; 80: 952-957.
3. Villhauer EB, Brinkman JA, Naderi G.B., Burkey B F, Dunning BE, Prasad K, Mangold B.L., Russell ME, Hughes TE 1-[[(3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl pepti-dase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003; 46: 2774-2789. (Pubitemid 36702545)
4. He YL, Sadler BM, Sabo R, Balez S., Wang Y, Campestrini J, Laurent A., Ligueros-Saylan M, Howard D. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vilda-gliptin, in healthy volunteers. Clin Pharmacoki-net. 2007; 46: 787-802. (Pubitemid 47347450)
5. Ahrén B., Simonsson E, Larsson H., Landin-Olsson M, Torgeirsson H, Jansson P.A., Sandqvist M., Båvenholm P, Efendic S., Eriksson J W, Dickinson S, Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002; 25: 869-875. (Pubitemid 41094285)
6. Ahrén B., Landin-Olsson M, Jansson P-A, Svensson M, Holmes D., Schweizer A. Inhibition of dipepti-dyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004; 89: 2078-2084. (Pubitemid 38619835)
7. Schweizer A, Dejager S, Foley J.E., Couturier A., Ligueros-Saylan M, Kothny W. Assessing the car-dio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010; 12: 485-494.
8. Schweizer A, Dejager S, Foley J.E., Kothny W. Assessing the general safety and tolerability of vilda-gliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag. 2011; 7: 49-57.
9. Ligueros-Saylan M., Foley JE, Schweizer A, Couturier A., Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab. 2010; 12: 495-509.
10. Pi-Sunyer F.X., Schweizer A, Mills D., Dejager S. Efficacy and tolerability of vildagliptin monother-apy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007; 76: 132-138. (Pubitemid 46240373)
11. Dejager S, Razac S, Foley J.E., Schweizer A. Vilda-gliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007; 39: 218-223.
12. Fonseca V, Schweizer A, Albrecht D., Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007; 50: 1148-1155. (Pubitemid 46701545)
13. Blonde L, Dagogo-Jack S, Banerji M.A., Pratley RE, Marcellari A, Braceras R, Purkayastha D., Baron M. Comparison of vildagliptin and thia-zolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. Diabetes Obes Metab. 2009; 11: 978-986.
14. Bosi E, Dotta F, Jia Y., Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monothera-py in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009; 11: 506-515.
15. Garber AJ, Schweizer A, Baron M.A., Rochotte E., Dejager S. Vildagliptin in combination with pio-glitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007; 9: 166-174. (Pubitemid 46206560)
16. He YL, Serra D, Wang Y., Campestrini J, Riviere GJ, Deacon C F, Holst JJ, Schwartz S, Nielsen J.C., Ligueros-Saylan M. Pharmacokinetics and phar-macodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007; 46: 577-588. (Pubitemid 47025358)
17. Sunkara G, Sabo R, Wang Y., He YL, Campestrini J, Rosenberg M, Howard D., Dole W P. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol. 2007; 47: 1152-1158.
18. He YL, Sabo R, Campestrini J., Wang Y, Riviere GJ, Nielsen J.C., Rosenberg M., Ligueros-Saylan M, Howard D, Dole W P. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol. 2008; 65: 338-346. (Pubitemid 351316915)
19. He H, Tran P, Yin H., Smith H, Batard Y, Wang L., Einolf H, Gu H, Mangold J.B., Fischer V., Howard D. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 2009; 37: 536-544.
20. He YL. Clinical pharmacokinetics and pharmaco-dynamics of vildagliptin. Clin Pharmacokinet. 2012; 51: 147-162.
21. He H, Tran P, Yin H., Smith H, Flood D, Kramp R., Filipeck R, Fischer V, Howard D. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. Drug Metab Dispos. 2009; 37: 545-554.
22. Retnakaran R, Cull CA, Thorne K.I., Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006; 55: 1832-1839. (Pubitemid 44324140)
23. Rossing P, de Zeeuw D. Need for better diabetes treatment for improved renal outcome. Kidney Int Suppl. 2011; 79 (Suppl 120): S28-S32.
24. Adler AI, Stevens RJ, Manley S.E., Bilous R W, Cull CA, Holman RR; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63: 225-232. (Pubitemid 35463925)
25. Young BA, Pugh JA, Maynard C, Reiber G. Diabetes and renal disease in veterans. Diabetes Care. 2004; 27 (Suppl 2): B45-B49. (Pubitemid 38569264)
26. Bretzel RG. Prevention and slowing down the progression of the diabetic nephropathy through anti-hypertensive therapy. J Diabetes Complications. 1997; 11: 112-122. (Pubitemid 27163208)
27. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B., De Smet M, Snyder K, Hilliard D., Tanen M, Tanaka W, Wang A.Q., Zeng W., Musson D, Winchell G, Davies M.J., Ramael S., Gottesdiener KM, Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005; 78: 675-688. (Pubitemid 41773643)
28. Harrower AD. Pharmacokinetics of oral antihy-perglycaemic agents in patients with renal insuf-ficiency. Clin Pharmacokinet. 1996; 31: 111-119. (Pubitemid 26252690)
29. Halimi S, Raccah D, Schweizer A., Dejager S. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin. 2010; 26: 1647-1656.
30. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009; 11: 804-812.
31. Schweizer A, Dejager S, Foley J.E., Shao Q., Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population > 75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011; 13: 55-64.
32. Dejager S, Schweizer A. Minimizing the risk of hy-poglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Ther. 2011; 2: 51-66.
33. Lam Y.W., Banerji S, Hatfield C., Talbert RL Principles of drug administration in renal insufficien-cy. Clin Pharmacokinet. 1997; 32: 30-57. (Pubitemid 27037847)
34. Lukashevich V, Schweizer A, Shao Q., Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011; 13: 947-954.
35. Banerji MA, Purkayastha D, Francis BH Safety and tolerability of vildagliptin vs. thiazolidinedi-one as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res Clin Pract. 2010; 90: 182-190.